MiMedx Group has enrolled the first patient in its Phase IIb clinical trial evaluating the safety and efficacy of AmnioFix Injectable as a treatment for pain associated with Osteoarthritis (OA) of the knee.

The investigational new drug (IND) trial is a double blinded, randomised controlled study that will enrol around 318 patients at 20 centres.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In the trial, patients will be randomised 1:1 in two treatment groups including a single injection of saline (placebo control) or a single 40mg dose of AmnioFix Injectable.

“AmnioFix Injectable has the opportunity to address a significant unmet clinical need by providing physicians and their patients with a new therapy for treating OA knee pain.”

The trial’s co-primary efficacy objects are the change in visual analog scale (VAS) score and the change in Western Ontario and McMaster Universities (WOMAC) osteoarthritis index between baseline and day 90 expressed as the difference in means between each group.

Its primary safety objective is the incidence of adverse, serious adverse, and unanticipated adverse events during the first 12 months post-injection in the AmnioFix Injectable group versus the placebo-controlled group.

MiMedx Group president and COO Bill Taylor said: “Given the lack of treatment options for patients with knee OA, and the high risks associated with using opioids to manage pain, AmnioFix Injectable has the opportunity to address a significant unmet clinical need by providing physicians and their patients with a new, safe, effective and durable front-line therapy for treating OA knee pain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“In addition, we believe AmnioFix Injectable has the potential to become a blockbuster therapeutic biologic, with long-term peak revenue potentially reaching $4bn for musculoskeletal pain management within the more than $12bn US joint pain injection market.”

OA of the knee is a degenerative and irreversible condition, which is related to pain, restricted mobility, and ultimately leads to joint instability.